7月17日，联合健康盘中上涨3.19%，报427.83美元/股，成交额8.92亿美元。
消息面上，公司前一日发布的Q2财报持续发酵，多家华尔街投行集中上调目标价。摩根士丹利将目标价从468美元大幅上调至529美元，美银全球研究从475美元上调至512美元，Cantor Fitzgerald从440美元上调至495美元，杰富瑞从401美元上调至490美元，派珀·桑德勒从477美元上调至499美元，均维持增持评级。
此轮目标价上调源于公司Q2调整后每股收益6.38美元，大幅超出市场预期的4.86美元，同时全年盈利指引从18.25美元以上上调至19.50至20.00美元。Truist指出，公司医疗护理比率改善、营收全面超预期，对下半年设定了更高预期。管理型保健护理板块中，哈门那同步上涨2.84%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.